All In Biotech

Drug Trial Radar · NCT05638776

Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy

A Multicenter, Randomized, Single-Blind, Placebo-Parallel-Controlled Research of REGEND001 Cell Therapy for Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Dec 6, 2022

Primary completion

Jul 9, 2025

Study completion Jul 9, 2025

Sponsor

Lead sponsor
Regend TherapeuticsIndustry
Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Guangzhou Medical University; Southwest Hospital, China; Shanghai Zhongshan Hospital; China-Japan Friendship Hospital; Shanghai East Hospital; Regend Therapeutics XLotus (Jiangxi) Co, Ltd.; The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central South University; The First Affiliated Hospital of Soochow University
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • REGEND001 cell therapyDrug

    Transplantation of the cell product

  • PlaceboDrug

    Transplantation of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responsive rate (RR)Time frame: 12 weeks after treatment, 24 weeks after treatment

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • The Southwest Hospital of AMU

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.